Fortress Biotech Inc (FBIO) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

Pharm_Hand Mar. 14 at 8:54 PM

$FBIO Fuckity fuck. Shuda cudda wudda swung it once it broke thru$4.

0 · Reply

IBUYSELLHOLD Mar. 13 at 11:14 PM

$FBIO daddy's going to take what is sold

0 · Reply

IBUYSELLHOLD Mar. 13 at 11:07 PM

$FBIO / i wonder who paid for advertising today

0 · Reply

IBUYSELLHOLD Mar. 13 at 10:19 PM

$FBIO /winner winner chicken 🐔 dinner

0 · Reply

braves1983 Mar. 13 at 10:08 PM

$FBIO still going down.

0 · Reply

braves1983 Mar. 13 at 8:02 PM

$FBIO I need to just get out of here. I lose $4K every fucking day here

2 · Reply

braves1983 Mar. 13 at 7:58 PM

$FBIO what a waste of a week. Back where we were. Just go to $2. Fuck it

0 · Reply

IBUYSELLHOLD Mar. 13 at 7:58 PM

$FBIO /daddy waits for you af

0 · Reply

braves1983 Mar. 13 at 7:58 PM

$FBIO wow still fucking tanking

0 · Reply

IBUYSELLHOLD Mar. 13 at 7:56 PM

$FBIO

0 · Reply

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

FBIOP

Feb 23, 2026, 8:30 AM EST - 20 days ago

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

FBIOP

Feb 23, 2026, 8:00 AM EST - 20 days ago

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

Feb 19, 2026, 9:38 PM EST - 23 days ago

Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap

Jan 13, 2026, 7:45 AM EST - 2 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

FBIOP

Dec 15, 2025, 8:00 AM EST - 3 months ago

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Dec 10, 2025, 8:30 AM EST - 3 months ago

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

DERM

Nov 14, 2025, 8:30 AM EST - 4 months ago

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Nov 12, 2025, 10:41 PM EST - 4 months ago

Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript

FBIOP

Nov 12, 2025, 4:01 PM EST - 4 months ago

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Nov 6, 2025, 7:00 AM EST - 4 months ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

AXSM

Nov 5, 2025, 8:30 AM EST - 4 months ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

DERM

Oct 24, 2025, 8:30 AM EDT - 5 months ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

DERM

Oct 21, 2025, 8:30 AM EDT - 5 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout

FBIOP

Oct 8, 2025, 8:30 AM EDT - 5 months ago

Journey Medical Corporation to Participate in October 2025 Investor Conferences

DERM

Oct 1, 2025, 3:45 PM EDT - 5 months ago

Fortress Biotech Investigated by the Portnoy Law Firm

Oct 1, 2025, 8:05 AM EDT - 5 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

FBIOP

Oct 1, 2025, 8:00 AM EDT - 5 months ago

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

FBIOP

Sep 3, 2025, 8:30 AM EDT - 6 months ago

Journey Medical Corporation to Participate in September 2025 Investor Conferences

DERM

Sep 2, 2025, 8:30 AM EDT - 6 months ago

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FBIOP

Aug 18, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation to Present at the Emerging Growth Conference

DERM

Aug 14, 2025, 4:05 PM EDT - 7 months ago

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Aug 12, 2025, 4:01 PM EDT - 7 months ago

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Aug 7, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

DERM

Aug 5, 2025, 4:01 PM EDT - 7 months ago

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

DERM

Jul 14, 2025, 8:30 AM EDT - 8 months ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

DERM

Jun 24, 2025, 8:30 AM EDT - 9 months ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

DERM

Jun 20, 2025, 8:30 AM EDT - 9 months ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

DERM

Jun 9, 2025, 8:30 AM EDT - 9 months ago

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

DERM

May 30, 2025, 10:47 AM EDT - 10 months ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIOP

May 15, 2025, 4:05 PM EDT - 10 months ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

May 14, 2025, 4:01 PM EDT - 10 months ago

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

May 13, 2025, 4:15 PM EDT - 10 months ago

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

CKPT

May 7, 2025, 4:01 PM EDT - 11 months ago

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

DERM

May 7, 2025, 8:00 AM EDT - 11 months ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

FBIOP

Apr 1, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

DERM

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

CKPT

Mar 26, 2025, 7:39 PM EDT - 1 year ago

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

FBIOP

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

DERM

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

DERM

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

DERM

Mar 17, 2025, 8:55 AM EDT - 1 year ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FBIOP

Mar 12, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

DERM

Mar 9, 2025, 10:06 PM EDT - 1 year ago

Sun Pharma to Acquire Checkpoint Therapeutics

CKPT

Mar 5, 2025, 4:15 PM EST - 1 year ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

MBIO

Mar 5, 2025, 4:01 PM EST - 1 year ago

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

DERM

Pharm_Hand Mar. 14 at 8:54 PM

$FBIO Fuckity fuck. Shuda cudda wudda swung it once it broke thru$4.

0 · Reply

IBUYSELLHOLD Mar. 13 at 11:14 PM

$FBIO daddy's going to take what is sold

0 · Reply

IBUYSELLHOLD Mar. 13 at 11:07 PM

$FBIO / i wonder who paid for advertising today

0 · Reply

IBUYSELLHOLD Mar. 13 at 10:19 PM

$FBIO /winner winner chicken 🐔 dinner

0 · Reply

braves1983 Mar. 13 at 10:08 PM

$FBIO still going down.

0 · Reply

braves1983 Mar. 13 at 8:02 PM

$FBIO I need to just get out of here. I lose $4K every fucking day here

2 · Reply

braves1983 Mar. 13 at 7:58 PM

$FBIO what a waste of a week. Back where we were. Just go to $2. Fuck it

0 · Reply

IBUYSELLHOLD Mar. 13 at 7:58 PM

$FBIO /daddy waits for you af

0 · Reply

braves1983 Mar. 13 at 7:58 PM

$FBIO wow still fucking tanking

0 · Reply

IBUYSELLHOLD Mar. 13 at 7:56 PM

$FBIO

0 · Reply

IBUYSELLHOLD Mar. 13 at 7:55 PM

$FBIO / no worries here boys, just shorts trying to have you sell

0 · Reply

braves1983 Mar. 13 at 7:35 PM

$FBIO everyday red. Why even look anymore

0 · Reply

Pharm_Hand Mar. 13 at 6:26 PM

$FBIO This is all biotech investors in general need to know about the last 5 years in small cap bios. There are far more similar charts to this than companies that have broken out of the bear trap:

1 · Reply

IBUYSELLHOLD Mar. 13 at 5:39 PM

$FBIO /half way there

1 · Reply

braves1983 Mar. 13 at 4:51 PM

$FBIO this piece of shit doesn’t stop going down. Just keep buying more and losing more.

3 · Reply

braves1983 Mar. 13 at 3:00 PM

$FBIO and yet another red fucking day here. Just doesn’t do shit ever. $17 price target my ass. Been months and months and months

0 · Reply

IBUYSELLHOLD Mar. 13 at 2:50 PM

$FBIO / just sitting here waiting for shorts to do some work 🙄, those shorts are just plain lazy!

0 · Reply

FinSUN Mar. 13 at 2:23 PM

$FBIO who is in the float matters more than anything, included poor technical analysis.

0 · Reply

dsoape Mar. 13 at 1:16 AM

$FBIO i loved the trading action today, a reversal off the gap lower & closes on the high of the day. tomorrow will tell , if we can get follow thru with a green day tomorrow, we should push back up to the 3.75 resistance level

0 · Reply

mulc Mar. 12 at 11:22 PM

$FBIO Check out Zellchair’s ”Fortress Biotech – The numbers that describe the uniqueness behind the company” article (March 2nd). It is one of the best infos an investor can find (you are gonna be shocked what is writen there - assuming this information is 100% true and verified) as I said before look out for next catalists this year their experts are now armed with ai platform, would not surprise me if we found another “triplex” this year.

0 · Reply

mulc Mar. 12 at 6:14 PM

$FBIO I mentioned this before and Zellchair also said it in one of his articles, for ”third” wave of drugs we might see fotress direct ownership of drugs imagine if we picked up one on 2026 :) that would be wild….”FB-606” having FB in drug‘s name looks dope have to be honest (just an example he gave not a real thing yet). So in 2026 the biggest potential news will be triplex data update, maybe updated pipline (new candidate), CAEL news, plan going forward or restructuring news.

1 · Reply

IBUYSELLHOLD Mar. 12 at 5:50 PM

$FBIO/ ya gotta manipulate the manipulators

1 · Reply

Market Cap	96.22M
Revenue (ttm)	57.68M
Net Income (ttm)	-46.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	5.29
Profit Margin	-79.75%
Debt to Equity Ratio	0.73

Volume	499,700
Avg Vol	1,119,778
Day's Range	N/A - N/A
Shares Out	31.04M
Stochastic %K	19%
Beta	1.38
Analysts	Strong Sell
Price Target	$10.75